Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Conditions: Melanoma; Non-small Cell Lung Cancer Interventions: Other: Evaluation of ctDNA using the F1T after 1 year of immunotherapy Sponsors: Massachusetts General Hospital; Foundation Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials